The increase in the export revenue is even higher than the increase in overall revenue of the company in the first half, with export revenue having doubled since the first half of 2020.
“The upward trend of drug exports recorded in the first half of 2024 compared with the first half of 2023 is the result of the continuation of Antibiotice’s development strategies, established by the “Territorial Expansion Plan”. Starting this year, we started selling injectable products in Italy, Poland, France, Bulgaria. In June, the first delivery was made to the United Arab Emirates market. We are planning to register new products to increase our presence in this market,” the company said in its latest financial report published on the Bucharest Stock Exchange website.
(English version by Loredana Fratila-Cristescu)